“In its Phase-III, the National Vaccine
Strategy aims at liberalised vaccine pricing and scaling up of vaccine coverage,” a statement issued by the Union Health Ministry said.
Vaccine manufacturers would supply 50 per cent of their approved monthly doses to the Centre, according to the vaccine policy for the third stage. They would be free to supply the other half to state governments and in the open market. This 50-50 division of supply would be applicable uniformly across for all vaccines manufactured in the country, while imported ones could be available fully in the open market, the statement elaborated.
The government has been working hard for over a year to ensure that maximum number of Indians are able to get vaccine in the shortest possible time,” Modi was quoted as saying in the statement. “Vaccine manufacturers are incentivized to further scale up their production, as well as attract new national and international players,” the statement added.
Manufacturers would have to transparently make an advance declaration of the price for 50 per cent supply that would be available to state governments and in the open market before May 1. Private hospitals would have to procure their supplies of Covid-19 vaccine exclusively from open market or through state governments. “Private vaccination providers shall transparently declare their self-set vaccination price.”
Based on the extent of infection and speed of vaccine administration, the Centre will also allocate vaccines to states from its own share. Wastage would be a factor which can work to the disadvantage of a state when getting its vaccine quota from the Centre. “State-wise quota would be decided and communicated to the states adequately in advance.”
Ten States including Maharashtra, Uttar Pradesh, Delhi, Karnataka, Kerala, Chhattisgarh, Madhya Pradesh, Tamil Nadu, Gujarat and Rajasthan reported nearly 80 per cent of the new cases.
All vaccinations would be part of the national vaccination programme, and mandated to follow all protocols such as entering data on the CoWIN platform, linked to adverse effects following immunisation (AEFI) reporting. Stocks and price per vaccination applicable in all vaccination centres will also have to be reported real-time.
The vaccine policy also said that the second dose of all existing priority groups wherever it has become due, would be given priority, for which a specific and focused strategy would be communicated to all stakeholders.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.